Objective Measurements of Physical Function to Predict Survival in Patients with Metastatic Cancer

References

• Nakano J, Fukushima T, Tanaka T, Fu JB, Morishita S. Physical function predicts mortality in patients with cancer: a systematic review and meta-analysis of observational studies. Support Care Cancer. 2021;29(10):5623–5624. doi: 10.1007/s00520-021-06171-3.
   PubMed Web of Science ®Google Scholar
• Verweij NM, Schiphorst AH, Pronk A, van den Bos F, Hamaker ME. Physical performance measures for predicting outcome in cancer patients: a systematic review. Acta Oncol. 2016;55(12):1386–1391. doi: 10.1080/0284186X.2016.1219047.
   PubMed Web of Science ®Google Scholar
• Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996;32A(7):1135–1141. doi: 10.1016/0959-8049(95)00664-8.
   PubMed Web of Science ®Google Scholar
• Paoli CJ, Bach BA, Quach D, Tsai KT, Wong B, Kallich J. Performance status of real-world oncology patients before and after first course of chemotherapy. J Community Support Oncol. 2014;12(5):163–170. doi:10.12788/jcso.0041.
   Google Scholar
• Simmons C, McMillan DC, Tuck S, Graham C, McKeown A, Bennett M, O’Neill C, Wilcock A, Usborne C, Fearon KC, IPAC Study Group, et al. How long have i got?"-a prospective cohort study comparing validated prognostic factors for use in patients with advanced cancer. Oncologist. 2019;24(9):e960–e967. doi: 10.1634/theoncologist.2018-0474.
   PubMed Web of Science ®Google Scholar
• Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the southwest oncology group experience. J Clin Oncol. 1991;9(9):1618–1626. voldoi: 10.1200/JCO.1991.9.9.1618.
   PubMed Web of Science ®Google Scholar
• Blagden SP, Charman SC, Sharples LD, Magee LRA, Gilligan D. Performance status score: do patients and their oncologists agree? Br J Cancer. 2003;89(6):1022–1027. doi: 10.1038/sj.bjc.6601231.
   PubMed Web of Science ®Google Scholar
• Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13(2):308–317. doi: 10.1093/annonc/mdf034.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98. doi: 10.1056/NEJMoa011954.
   PubMed Web of Science ®Google Scholar
• Sengelov L, Kamby C, Geertsen P, Andersen LJ, von der Maase H. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Pharmacol. 2000;46(5):357–364. doi: 10.1007/s002800000176.
   PubMed Web of Science ®Google Scholar
• Sculier JP, Lafitte JJ, Paesmans M, Thiriaux J, Alexopoulos CG, Baumöhl J, Schmerber J, Koumakis G, Florin MC, Zacharias C, et al. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer. 2000;83(9):1128–1135. doi: 10.1054/bjoc.2000.1413.
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005;23(1):190–196. doi: 10.1200/JCO.2005.07.172.
   PubMed Web of Science ®Google Scholar
• Sculier JP, Lafitte JJ, Paesmans M, Lecomte J, Alexopoulos CG, Van Cutsem O, Giner V, Efremidis A, Berchier MC, Collon T, European Lung Cancer Working Party, et al. Chemotherapy improves low performance status lung cancer patients. Eur Respir J. 2007;30(6):1186–1192. doi: 10.1183/09031936.00034507.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655.
   PubMed Web of Science ®Google Scholar
• Fairclough DL, Cella DF. Eastern Cooperative Oncology Group (ECOG). J Natl Cancer Inst Monogr. 1996;(20):73–5. PMID: 8750470.
   PubMedGoogle Scholar
• Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824–1831. doi: 10.1200/JCO.2007.10.6559.
   PubMed Web of Science ®Google Scholar
• Scott JM, Stene G, Edvardsen E, Jones LW. Performance status in cancer: not broken, but time for an upgrade? J Clin Oncol. 2020;38(25):2824–2829. doi: 10.1200/JCO.20.00721.
   PubMed Web of Science ®Google Scholar
• Kilgour RD, Vigano A, Trutschnigg B, Lucar E, Borod M, Morais JA. Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer. 2013;21(12):3261–3270. doi: 10.1007/s00520-013-1894-4.
   PubMed Web of Science ®Google Scholar
• Klepin HD, Geiger AM, Tooze JA, Newman AB, Colbert LH, Bauer DC, Satterfield S, Pavon J, Kritchevsky SB, Health, Aging and Body Composition Study Physical performance and subsequent disability and survival in older adults with malignancy: results from the health, aging and body composition study. J Am Geriatr Soc. 2010;58(1):76–82. doi: 10.1111/j.1532-5415.2009.02620.x.
   PubMed Web of Science ®Google Scholar
• Wiegert EVM, da Silva NF, de Oliveira LC, Calixto-Lima L. Reference values for handgrip strength and their association with survival in patients with incurable cancer. Eur J Clin Nutr. 2022;76(1):93–102. doi: 10.1038/s41430-021-00921-6.
   PubMed Web of Science ®Google Scholar
• Versteeg KS, Blauwhoff-Buskermolen S, Buffart LM, de van der Schueren MAE, Langius JAE, Verheul HMW, Maier AB, Konings IR. Higher muscle strength is associated with prolonged survival in older patients with advanced cancer. Oncologist. 2018;23(5):580–585. doi: 10.1634/theoncologist.2017-0193.
   PubMed Web of Science ®Google Scholar
• Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000;88(9):2164–2171. doi:10.1002/(sici)1097-0142(20000501)88:9 < 2164::aid-cncr24 > 3.0.co;2-5.
   PubMed Web of Science ®Google Scholar
• Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Nutr Rev. 1996;54(1 Pt 2):S59–S65. doi: 10.1111/j.1753-4887.1996.tb03793.x.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• World Health Organization 2013. International classification of diseases for oncology (ICD-O). 3rd ed., 1st revision. Geneva, Switzerland: World Health Organization. https://apps.who.int/iris/handle/10665/96612. Accessed 15 June 2022.
   Google Scholar
• Leong DP, Teo KK, Rangarajan S, Lopez-Jaramillo P, Avezum A, Jr, Orlandini A, Seron P, Ahmed SH, Rosengren A, Kelishadi R, Prospective Urban Rural Epidemiology (PURE) Study investigators, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015;386(9990):266–273. doi: 10.1016/S0140-6736(14)62000-6.
   PubMed Web of Science ®Google Scholar
• Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999;70(2):113–119. doi: 10.1080/02701367.1999.10608028.
   PubMed Web of Science ®Google Scholar
• Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–148. doi: 10.1111/j.1532-5415.1991.tb01616.x.
   PubMed Web of Science ®Google Scholar
• Rydwik E, Bergland A, Forsen L, Frändin K. Investigation into the reliability and validity of the measurement of elderly people’s clinical walking speed: a systematic review. Physiother Theory Pract. 2012;28(3):238–256. doi: 10.3109/09593985.2011.601804.
   PubMedGoogle Scholar
• https://www.nia.nih.gov/research/labs/leps/short-physical-performance-battery-sppb. Short Physical Performance Battery. [Cited 2022 May 15].
   Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi: 10.1093/ageing/afy169. Erratum in: Age Ageing. 2019 Jul 1;48(4):601.
   PubMed Web of Science ®Google Scholar
• Maggio M, Ceda GP, Ticinesi A, De Vita F, Gelmini G, Costantino C, Meschi T, Kressig RW, Cesari M, Fabi M, et al. Instrumental and non-instrumental evaluation of 4-meter walking speed in older individuals. PLoS One. 2016;11(4):e0153583. doi: 10.1371/journal.pone.0153583.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer therapy evaluation program, common toxicity criteria. Version 2.0. Bethesda, MD: National Cancer Institute 1999.
   Google Scholar
• Laird BJ, Fallon M, Hjermstad MJ, Tuck S, Kaasa S, Klepstad P, McMillan DC. Quality of life in patients with advanced cancer: differential association with performance status and systemic inflammatory response. J Clin Oncol. 2016;34(23):2769–2775. doi: 10.1200/JCO.2015.65.7742.
   PubMed Web of Science ®Google Scholar
• Dolan RD, Daly LE, Simmons CP, Ryan AM, Sim WM, Fallon M, Power DG, Wilcock A, Maddocks M, Bennett MI, et al. The relationship between ECOG-PS, mGPS, BMI/WL grade and body composition and physical function in patients with advanced cancer. Cancers. 2020;12(5):1187. doi: 10.3390/cancers12051187.
   PubMed Web of Science ®Google Scholar
• Dolan RD, Daly L, Sim WMJ, Fallon M, Ryan A, McMillan DC, Laird BJ. Comparison of the prognostic value of ECOG-PS, mGPS and BMI/WL: Implications for a clinically important framework in the assessment and treatment of advanced cancer. Clin Nutr. 2020;39(9):2889–2895. doi: 10.1016/j.clnu.2019.12.024.
   PubMed Web of Science ®Google Scholar
• Soubeyran P, Fonck M, Blanc-Bisson C, Blanc JF, Ceccaldi J, Mertens C, Imbert Y, Cany L, Vogt L, Dauba J, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012;30(15):1829–1834. doi: 10.1200/JCO.2011.35.7442.
   PubMed Web of Science ®Google Scholar
• Ferrat E, Paillaud E, Laurent M, Le Thuaut A, Caillet P, Tournigand C, Lagrange JL, Canouï-Poitrine F, Bastuji-Garin SES, Group Predictors of 1-Year Mortality in a Prospective Cohort of Elderly Patients With Cancer. J Gerontol A Biol Sci Med Sci. 2015;70(9):1148–1155. doi: 10.1093/gerona/glv025.
   PubMed Web of Science ®Google Scholar
• Deschler B, Ihorst G, Schnitzler S, Bertz H, Finke J. Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis. Bone Marrow Transplant. 2018 May;53(5):565–575. doi: 10.1038/s41409-017-0021-4.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Eckardt R, Altmeppen S, Wernecke KD, Spies C. Functional impairment prior to major non-cardiac surgery is associated with mortality within one year in elderly patients with gastrointestinal, gynaecological and urogenital cancer: A prospective observational cohort study. J Geriatr Oncol. 2018;9(1):53–59. doi: 10.1016/j.jgo.2017.07.011.
   PubMed Web of Science ®Google Scholar
• Salas MQ, Atenafu EG, Bascom O, Wilson L, Lam W, Law AD, Pasic I, Kim DDH, Michelis FV, Al-Shaibani Z, et al. Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021;56(1):60–69. doi: 10.1038/s41409-020-0979-1.
   PubMed Web of Science ®Google Scholar
• Cesari M, Cerullo F, Zamboni V, Di Palma R, Scambia G, Balducci L, Antonelli Incalzi R, Vellas B, Gambassi G. Functional status and mortality in older women with gynecological cancer. J Gerontol A Biol Sci Med Sci. 2013;68(9):1129–1133. doi: 10.1093/gerona/glt073.
   PubMed Web of Science ®Google Scholar
• Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013; 121(21):4287–4294. doi: 10.1182/blood-2012-12-471680.
   PubMed Web of Science ®Google Scholar
• Pamoukdjian F, Lévy V, Sebbane G, Boubaya M, Landre T, Bloch-Queyrat C, Paillaud E, Zelek L. Slow gait speed is an independent predictor of early death in older cancer outpatients: results from a prospective cohort study. J Nutr Health Aging. 2017;21(2):202–206. doi: 10.1007/s12603-016-0734-x.
   PubMed Web of Science ®Google Scholar
• Pamoukdjian F, Aparicio T, Zebachi S, Zelek L, Paillaud E, Canoui-Poitrine F. Comparison of mobility indices for predicting early death in older patients with cancer: The physical frailty in elderly cancer cohort study. J Gerontol A Biol Sci Med Sci. 2020; 75(1):189–196. doi: 10.1093/gerona/glz024.
   PubMed Web of Science ®Google Scholar
• Liu MA, DuMontier C, Murillo A, Hshieh TT, Bean JF, Soiffer RJ, Stone RM, Abel GA, Driver JA. Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood. 2019;134(4):374–382. doi: 10.1182/blood.2019000758.
   PubMed Web of Science ®Google Scholar
• Burtin C, Bezuidenhout J, Sanders KJC, Dingemans A-MC, Schols AMWJ, Peeters STH, Spruit MA, De Ruysscher DKM. Handgrip weakness, low fat-free mass, and overall survival in non-small cell lung cancer treated with curative-intent radiotherapy. J Cachexia Sarcopenia Muscle. 2020;11(2):424–431. doi: 10.1002/jcsm.12526.
   PubMed Web of Science ®Google Scholar
• Zhuang CL, Zhang FM, Li W, Wang KH, Xu HX, Song CH, Guo ZQ, Shi HP. Associations of low handgrip strength with cancer mortality: a multicentre observational study. J Cachexia Sarcopenia Muscle. 2020;11(6):1476–1486. doi: 10.1002/jcsm.12614.
   PubMed Web of Science ®Google Scholar
• Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752–762. doi: 10.1016/S0140-6736(12)62167-9.
   PubMed Web of Science ®Google Scholar
• Huisman MG, van Leeuwen BL, Ugolini G, Montroni I, Spiliotis J, Stabilini C, de’Liguori Carino N, Farinella E, de Bock GH, Audisio RA. Timed up & go": a screening tool for predicting 30-day morbidity in onco-geriatric surgical patients? A multicenter cohort study. PLoS One. 2014;9(1):e86863. doi: 10.1371/journal.pone.0086863.
   PubMed Web of Science ®Google Scholar
• Kelly CM, Shahrokni A. Moving beyond Karnofsky and ECOG performance status assessments with new technologies. J Oncol. 2016;2016:6186543. doi: 10.1155/2016/6186543.
   PubMed Web of Science ®Google Scholar
• Laird BJA, Balstad TR, Solheim TS. Endpoints in clinical trials in cancer cachexia: where to start? Curr Opin Support Palliat Care. 2018;12(4):445–452. doi: 10.1097/SPC.0000000000000387.
   PubMed Web of Science ®Google Scholar
• Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519–531. doi: 10.1016/S1470-2045(15)00558-6.
   PubMed Web of Science ®Google Scholar
• Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, Canin B, Cohen HJ, Holmes HM, Hopkins JO, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326–2347. doi: 10.1200/JCO.2018.78.8687.
   PubMed Web of Science ®Google Scholar
• Driscoll JJ, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. Cancer J. 2009;15(5):401–405. doi: 10.1097/PPO.0b013e3181bdc2e0.
   PubMed Web of Science ®Google Scholar
• Wilson MK, Karakasis K, Oza AM. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncol. 2015;16(1):e32–e42. doi: 10.1016/S1470-2045(14)70375-4.
   PubMed Web of Science ®Google Scholar
• Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008;13 Suppl 2:19–21. doi: 10.1634/theoncologist.13-S2-19.
   PubMed Web of Science ®Google Scholar
• Sullivan R. Clinical trial design in oncology: protocol design. Lancet Oncol. 2004;5(12):759. doi: 10.1016/S1470-2045(04)01654-7.
   PubMed Web of Science ®Google Scholar
• Trask PC, Hsu MA, McQuellon R. Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance. Cancer J. 2009;15(5):435–440. doi: 10.1097/PPO.0b013e3181b9c5b9.
   PubMed Web of Science ®Google Scholar